12:00 AM
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALN-TTR02: Completed Phase I enrollment

Alnylam completed enrollment of 17 healthy volunteers in a single-blind, placebo-controlled, U.K. Phase I trial evaluating single ascending-doses of 0.01-0.50 mg/kg...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >